Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

Here is how Adma Biologics (ADMA) and Artivion (AORT) have performed compared to their sector so far this year.

Zacks Investment Research • Dec 12, 2025

Adma Biologics (ADMA) Up 43.3% Since Last Earnings Report: Can It Continue?

Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 5, 2025

Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research • Dec 1, 2025

Wall Street Analysts Think Adma Biologics (ADMA) Could Surge 60.24%: Read This Before Placing a Bet

The consensus price target hints at a 60.2% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 27, 2025

Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?

Here is how Adma Biologics (ADMA) and Cronos Group (CRON) have performed compared to their sector so far this year.

Zacks Investment Research • Nov 25, 2025

Adma Biologics (ADMA) Upgraded to Buy: Here's What You Should Know

Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Nov 25, 2025

Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average

After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.

Zacks Investment Research • Nov 25, 2025

ADMA Biologics: Why The Dip To $16 Resets The Buy Case

ADMA Biologics remains a Buy as Q3 results and 2026 guidance support a bullish long-term outlook. ADMA's Asceniv drives robust revenue and margin expansion, with 2026 revenue guided at $630M and EBITDA margin at 56%. Yield-enhanced manufacturing and facility expansion position ADMA for further growth, while SG-001 offers optionality beyond 2029.

Seeking Alpha • Nov 20, 2025

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • Nov 14, 2025

Adma Biologics (ADMA) Crossed Above the 50-Day Moving Average: What That Means for Investors

Adma Biologics (ADMA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ADMA broke through the 50-day moving average, which suggests a short-term bullish trend.

Zacks Investment Research • Nov 12, 2025